Role of Hypoxia and Glycolysis in the Development of Multi-drug Resistance in Human Tumor Cells and the Establishment of an Orthotopic Multi-drug Resistant Tumor Model in Nude Mice Using Hypoxic Pre-conditioning

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2011 Feb 16

PMID 21320311

Citations 54

Authors

Lara Milane

Zhenfeng Duan

Mansoor Amiji

Affiliations

Soon will be listed here.

Abstract

Background: The development of multi-drug resistant (MDR) cancer is a significant challenge in the clinical treatment of recurrent disease. Hypoxia is an environmental selection pressure that contributes to the development of MDR. Many cancer cells, including MDR cells, resort to glycolysis for energy acquisition. This study aimed to explore the relationship between hypoxia, glycolysis, and MDR in a panel of human breast and ovarian cancer cells. A second aim of this study was to develop an orthotopic animal model of MDR breast cancer.

Methods: Nucleic and basal protein was extracted from a panel of human breast and ovarian cancer cells; MDR cells and cells pre-exposed to either normoxic or hypoxic conditions. Western blotting was used to assess the expression of MDR markers, hypoxia inducible factors, and glycolytic proteins. Tumor xenografts were established in the mammary fat pad of nu/nu mice using human breast cancer cells that were pre-exposed to either hypoxic or normoxic conditions. Immunohistochemistry was used to assess the MDR character of excised tumors.

Results: Hypoxia induces MDR and glycolysis in vitro, but the cellular response is cell-line specific and duration dependent. Using hypoxic, triple-negative breast cancer cells to establish 100 mm3 tumor xenografts in nude mice is a relevant model for MDR breast cancer.

Conclusion: Hypoxic pre-conditiong and xenografting may be used to develop a multitude of orthotopic models for MDR cancer aiding in the study and treatment of the disease.

Citing Articles

Alterations in genes involved in glycolysis and hypoxia affect the prognosis of pancreatic cancer.

Huang Y, Zhu Q, Sun Y, Zhang W, Zou J Heliyon. 2024; 10(14):e34104.

PMID: 39100466 PMC: 11295968. DOI: 10.1016/j.heliyon.2024.e34104.

NF-κB mediated regulation of tumor cell proliferation in hypoxic microenvironment.

Rastogi S, Aldosary S, Saeedan A, Ansari M, Singh M, Kaithwas G Front Pharmacol. 2023; 14:1108915.

PMID: 36891273 PMC: 9986608. DOI: 10.3389/fphar.2023.1108915.

A Proposed Association between Improving Energy Metabolism of HepG2 Cells by Plant Extracts and Increasing Their Sensitivity to Doxorubicin.

Al-Shafie T, Mahrous E, Shukry M, Alshahrani M, Ibrahim S, Fericean L Toxics. 2023; 11(2).

PMID: 36851057 PMC: 9967676. DOI: 10.3390/toxics11020182.

Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.

Todosenko N, Yurova K, Khaziakhmatova O, Malashchenko V, Khlusov I, Litvinova L Pharmaceutics. 2022; 14(10).

PMID: 36297616 PMC: 9612132. DOI: 10.3390/pharmaceutics14102181.

Abnormal expression of HADH, an enzyme of fatty acid oxidation, affects tumor development and prognosis (Review).

Wang X, Song H, Liang J, Jia Y, Zhang Y Mol Med Rep. 2022; 26(6).

PMID: 36239258 PMC: 9607826. DOI: 10.3892/mmr.2022.12871.

References

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

Young C, Anderson S . Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008; 10(1):202. PMC: 2374962. DOI: 10.1186/bcr1852. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

Depping R, Steinhoff A, Schindler S, Friedrich B, Fagerlund R, Metzen E . Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim Biophys Acta. 2008; 1783(3):394-404. DOI: 10.1016/j.bbamcr.2007.12.006. View

Vaupel P . Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004; 14(3):198-206. DOI: 10.1016/j.semradonc.2004.04.008. View

Maddika S, Ande S, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A . Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007; 10(1-2):13-29. DOI: 10.1016/j.drup.2007.01.003. View

Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View

Jamroziak K, Robak T . Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology. 2004; 9(2):91-105. DOI: 10.1080/10245330310001638974. View

Nanduri J, Yuan G, Kumar G, Semenza G, Prabhakar N . Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol. 2008; 164(1-2):277-81. PMC: 3390913. DOI: 10.1016/j.resp.2008.07.006. View

10.

Hockel M, Vaupel P . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93(4):266-76. DOI: 10.1093/jnci/93.4.266. View

11.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

12.

Loges S, Mazzone M, Hohensinner P, Carmeliet P . Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009; 15(3):167-70. DOI: 10.1016/j.ccr.2009.02.007. View

13.

Cuezva J, Ortega A, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M . The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta. 2009; 1792(12):1145-58. DOI: 10.1016/j.bbadis.2009.01.006. View

14.

Smaldone M, Maranchie J . Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol. 2009; 27(3):238-45. DOI: 10.1016/j.urolonc.2007.12.001. View

15.

Lemos C, Jansen G, Peters G . Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer. 2008; 98(5):857-62. PMC: 2266858. DOI: 10.1038/sj.bjc.6604213. View

16.

Campbell R, Ying B, Kuesters G, Hemphill R . Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2008; 98(2):411-29. DOI: 10.1002/jps.21458. View

17.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

18.

Liu H, Savaraj N, Priebe W, Lampidis T . Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol. 2002; 64(12):1745-51. DOI: 10.1016/s0006-2952(02)01456-9. View

19.

Robey I, Lien A, Welsh S, Baggett B, Gillies R . Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia. 2005; 7(4):324-30. PMC: 1501147. DOI: 10.1593/neo.04430. View

20.

Seagroves T, RYAN H, Lu H, Wouters B, Knapp M, Thibault P . Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001; 21(10):3436-44. PMC: 100265. DOI: 10.1128/MCB.21.10.3436-3444.2001. View